IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Nabriva Therapeutics PLC

CUSIP: G63637955 | 4 institutional holders

Quarters

Q3 2020Q2 2020Q1 2020Q4 2019Q3 2019
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile